Vimarsana
Biggest News Aggregation in the World

Page 6 - Advanced Solid Tumors News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Advanced Solid Tumors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Advanced Solid Tumors Today - Breaking & Trending Today

Dr Kirtane on the Design of the EVEREST-1 Trial Evaluating A2B530 in Solid Tumors - Vimarsana News

Dr Kirtane on the Design of the EVEREST-1 Trial Evaluating A2B530 in Solid Tumors

Kedar Kirtane, MD, discusses the design of the phase 1/2 EVEREST-1 trial, which is evaluating the autologous CAR T-cell therapy A2B530 in patients with advanced solid tumors.

Evaxion's AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial - Vimarsana News

Evaxion's AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today presented promising clinical data from its EVX-01 Phase 1 dose escalation trial in metastatic melanoma at the 2023 ASCO annual meeting in ...

Daiichi Sankyo : ENHERTU® Demonstrated Clinically Meaningful and Durable Responses in Patients Across Multiple HER2 Expressing Advanced Solid Tumors(414.1KB - Vimarsana News

Daiichi Sankyo : ENHERTU® Demonstrated Clinically Meaningful and Durable Responses in Patients Across Multiple HER2 Expressing Advanced Solid Tumors(414.1KB

Press Release ENHERTU® Demonstrated Clinically Meaningful and Durable Responses in Patients Across Multiple HER2 Expressing Advanced Solid Tumors ... | June 5, 2023

Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO - Vimarsana News

Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO

AGEN2373 is the first CD137 agonist antibody reporting single agent responses with no major toxicity Responses reported in patients with prostate cancer, ampullary carcinoma and metastatic vulvar... | June 5, 2023

Evaxion Biotech: Evaxion's AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial - Vimarsana News

Evaxion Biotech: Evaxion's AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial

The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerabilityPositive clinical responses were reported in 8 out of 12 EVX-01 treated patientsHigh-quality